white-border-top

ABOUT US

we are passionate in our commitment to saving and renewing the lives of people with cancer.

We are a late-stage company developing fusion protein medicines. Our fusion protein approach tethers a tumor-targeting antibody fragment to a protein cytotoxic payload to form a single protein molecule designed to selectively and broadly kill cancer cells while minimizing toxicity to healthy cells and to activate the body’s innate immune response system.

management

Thomas Cannell, DVM

President & Chief Executive Officer

Gregory P. Adams, Ph.D.

Chief Scientific Officer

Dennis Kim, M.D., MPH

Chief Medical Officer

Glen MacDonald, Ph.D.

Chief Technology Officer

Richard F. Fitzgerald

Chief Financial Officer

Mark R. Sullivan

General Counsel

Madhu Anant M.Sc., Ph.D., RAC

Vice President, Regulatory Affairs

board of directors

Wendy L. Dixon, Ph.D.

Chairwoman of the Board of Directors

Thomas Cannell, DVM

President & Chief Executive Officer

Leslie L. Dan, B.Sc. Phm., M.B.A., C.M.

Director

Jay S. Duker, M.D.

Director

Jane V. Henderson

Director

Daniel S. Lynch

Director

RENEW LIFE

change lives with us

We are a group of motivated individuals who are committed to changing lives for the better. Learn more about our open positions and how you can renew life with us.

Learn More
Top